{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:13:24Z","timestamp":1790702004969,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T00:00:00Z","timestamp":1276128000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1471-2407-10-277","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T18:59:03Z","timestamp":1276196343000},"source":"Crossref","is-referenced-by-count":19,"title":["Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists"],"prefix":"10.1186","volume":"10","author":[{"given":"Nicolas","family":"Methy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bedenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,10]]},"reference":[{"issue":"Suppl 2","key":"2076_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","volume":"13","author":"R Pazdur","year":"2008","unstructured":"Pazdur R: Endpoints for assessing drug activity in clinical trials. Oncologist. 2008, 13 (Suppl 2): 19-21. 10.1634\/theoncologist.13-S2-19.","journal-title":"Oncologist"},{"issue":"4","key":"2076_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/annonc\/mdh127","volume":"15","author":"A Di Leo","year":"2004","unstructured":"Di Leo A, Buyse M, Bleiberg H: Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol. 2004, 15 (4): 545-549. 10.1093\/annonc\/mdh127.","journal-title":"Ann Oncol"},{"issue":"3","key":"2076_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001, 69 (3): 89-95. 10.1067\/mcp.2001.113989.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2076_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/sim.2319","volume":"25","author":"CJ Weir","year":"2006","unstructured":"Weir CJ, Walley RJ: Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med. 2006, 25 (2): 183-203. 10.1002\/sim.2319.","journal-title":"Stat Med"},{"issue":"2","key":"2076_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","volume":"14","author":"Q Shi","year":"2009","unstructured":"Shi Q, Sargent DJ: Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol. 2009, 14 (2): 102-111. 10.1007\/s10147-009-0885-4.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2076_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/annonc\/mdp340","volume":"21","author":"N Methy","year":"2009","unstructured":"Methy N, Bedenne L, Conroy T, Bouche O, Chapet O, Ducreux M, Gerard JP, Bonnetain F: Surrogate endpoints in neoadjuvant rectal cancer trials: Statistical evaluation using data from the FFCD 9203 trial. Ann Oncol. 2009, 21 (3): 518-524. 10.1093\/annonc\/mdp340.","journal-title":"Ann Oncol"},{"issue":"5","key":"2076_CR7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1684\/bdc.2009.0858","volume":"96","author":"N Methy","year":"2009","unstructured":"Methy N, Bedenne L, Bonnetain F: [Validation of surrogate endpoints in digestive oncology]. Bull Cancer. 2009, 96 (5): 591-595.","journal-title":"Bull Cancer"},{"issue":"34","key":"2076_CR8","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005, 23 (34): 8664-8670. 10.1200\/JCO.2005.01.6071.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2076_CR9","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","volume":"25","author":"DJ Sargent","year":"2007","unstructured":"Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, et al: End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007, 25 (29): 4569-4574. 10.1200\/JCO.2006.10.4323.","journal-title":"J Clin Oncol"},{"issue":"29","key":"2076_CR10","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang PA, Bentzen SM, Chen EX, Siu LL: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007, 25 (29): 4562-4568. 10.1200\/JCO.2006.08.1935.","journal-title":"J Clin Oncol"},{"issue":"33","key":"2076_CR11","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007, 25 (33): 5218-5224. 10.1200\/JCO.2007.11.8836.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2076_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H: Research guidelines for the Delphi survey technique. J Adv Nurs. 2000, 32 (4): 1008-1015. 10.1046\/j.1365-2648.2000.01567.x.","journal-title":"J Adv Nurs"},{"issue":"2","key":"2076_CR13","first-page":"96","volume":"12","author":"B Kassa\u00ef","year":"2006","unstructured":"Kassa\u00ef B, Gueyffier F, Boissel JP: Crit\u00e8res interm\u00e9diaires et crit\u00e8res de substitution. M\u00e9decine Th\u00e9rapeutique. 2006, 12 (2): 96-103.","journal-title":"M\u00e9decine Th\u00e9rapeutique"},{"issue":"4","key":"2076_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989, 8 (4): 431-440. 10.1002\/sim.4780080407.","journal-title":"Stat Med"},{"issue":"9227","key":"2076_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","volume":"356","author":"M Buyse","year":"2000","unstructured":"Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000, 356 (9227): 373-378. 10.1016\/S0140-6736(00)02528-9.","journal-title":"Lancet"},{"issue":"9","key":"2076_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","volume":"7","author":"KR Johnson","year":"2006","unstructured":"Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, Hill SR, Ward RL: Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006, 7 (9): 741-746. 10.1016\/S1470-2045(06)70800-2.","journal-title":"Lancet Oncol"},{"issue":"15S suppl","key":"2076_CR17","doi-asserted-by":"crossref","first-page":"abstr 4517","DOI":"10.1200\/jco.2009.27.15_suppl.4517","volume":"27","author":"T Burzykowski","year":"2009","unstructured":"Burzykowski T, Bang Y, on behalf of the GASTRIC project. : Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol. 2009, 27 (15S suppl): abstr 4517-","journal-title":"J Clin Oncol"},{"issue":"10","key":"2076_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ejca.2006.02.011","volume":"42","author":"L Collette","year":"2006","unstructured":"Collette L, Burzykowski T, Schroder FH: Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer. 2006, 42 (10): 1344-1350. 10.1016\/j.ejca.2006.02.011.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2076_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.eururo.2007.08.041","volume":"53","author":"L Collette","year":"2008","unstructured":"Collette L: Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials. Eur Urol. 2008, 53 (1): 6-9. 10.1016\/j.eururo.2007.08.041.","journal-title":"Eur Urol"},{"issue":"7","key":"2076_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996, 125 (7): 605-613.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2076_CR21","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","volume":"21","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003, 21 (7): 1404-1411. 10.1200\/JCO.2003.08.072.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2076_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","volume":"93","author":"G Apolone","year":"2005","unstructured":"Apolone G, Joppi R, Bertele V, Garattini S: Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer. 2005, 93 (5): 504-509. 10.1038\/sj.bjc.6602750.","journal-title":"Br J Cancer"},{"issue":"1","key":"2076_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","volume":"24","author":"TR Fleming","year":"2005","unstructured":"Fleming TR: Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood). 2005, 24 (1): 67-78. 10.1377\/hlthaff.24.1.67.","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"2076_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/pst.309","volume":"7","author":"K Carroll","year":"2008","unstructured":"Carroll K, Ross HC, Evans D, France L, Hemmings R, Hughes S, Lynn F, Mahoney P, Phillips A: Conditional approval: discussion points from the PSI conditional approval expert group. Pharm Stat. 2008, 7 (4): 263-269. 10.1002\/pst.309.","journal-title":"Pharm Stat"},{"issue":"17","key":"2076_CR25","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","volume":"27","author":"TR Fleming","year":"2009","unstructured":"Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009, 27 (17): 2874-2880. 10.1200\/JCO.2008.20.4107.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2076_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(06)70839-7","volume":"7","author":"F Perrone","year":"2006","unstructured":"Perrone F: Don't forget survival, please. Lancet Oncol. 2006, 7 (9): 703-704. 10.1016\/S1470-2045(06)70839-7.","journal-title":"Lancet Oncol"},{"issue":"34","key":"2076_CR27","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1200\/JCO.2005.03.6186","volume":"23","author":"J Abrams","year":"2005","unstructured":"Abrams J: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: a commentary. J Clin Oncol. 2005, 23 (34): 8564-8565. 10.1200\/JCO.2005.03.6186.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2076_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/0962280207081853","volume":"17","author":"A Grothey","year":"2008","unstructured":"Grothey A: Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res. 2008, 17 (5): 529-535. 10.1177\/0962280207081853.","journal-title":"Stat Methods Med Res"},{"issue":"22","key":"2076_CR29","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1200\/JCO.2007.14.1192","volume":"26","author":"S Mathoulin-Pelissier","year":"2008","unstructured":"Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A: Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol. 2008, 26 (22): 3721-3726. 10.1200\/JCO.2007.14.1192.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2076_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","volume":"100","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008, 100 (10): 698-711. 10.1093\/jnci\/djn134.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"2076_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/jnci\/djm024","volume":"99","author":"CJ Punt","year":"2007","unstructured":"Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobrero A, Douillard JY: Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007, 99 (13): 998-1003. 10.1093\/jnci\/djm024.","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2076_CR32","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1200\/JCO.2007.12.1368","volume":"25","author":"C Allegra","year":"2007","unstructured":"Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D: End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007, 25 (24): 3572-3575. 10.1200\/JCO.2007.12.1368.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2076_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdp523","volume":"21","author":"ED Saad","year":"2010","unstructured":"Saad ED, Katz A, Hoff PM, Buyse M: Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010, 21 (1): 7-12. 10.1093\/annonc\/mdp523.","journal-title":"Ann Oncol"},{"issue":"28","key":"2076_CR34","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP Gerard","year":"2006","unstructured":"Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006, 24 (28): 4620-4625. 10.1200\/JCO.2006.06.7629.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2076_CR35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006, 355 (11): 1114-1123. 10.1056\/NEJMoa060829.","journal-title":"N Engl J Med"},{"key":"2076_CR36","unstructured":"Beitz J, Gnecco C, Justice R: Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996, 7-9. 20"},{"issue":"11","key":"2076_CR37","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1200\/JCO.1998.16.11.3662","volume":"16","author":"JA Sloan","year":"1998","unstructured":"Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL: Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998, 16 (11): 3662-3673.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-277\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T08:30:23Z","timestamp":1635496223000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,10]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["2076"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-277","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,10]]},"article-number":"277"}}